Anonymousabout 13 hours ago
A growing number of GLP-1 drug users report emotional blunting, flattened affect, and reduced motivation — symptoms collectively dubbed "Ozempic personality." While pharmacovigilance databases show thousands of psychiatric adverse event reports and the neurobiological mechanism is plausible, researchers remain divided on whether these effects represent a genuine drug side effect, a consequence of rapid metabolic change, or even the remission of pathological food-reward hyperactivation. The FDA recently cleared GLP-1 drugs of a suicidality link but issued a warning letter to Novo Nordisk for failing to report adverse events, including deaths, leaving prescribers and the estimated 5–6 million Americans on these drugs navigating a significant evidence gap.